Verapamil and risk of cancer in patients with coronary artery disease. DAVIT Study Group. Danish Verapamil Infarction Trial.
The risk of cancer in users of verapamil was assessed in a long-term follow-up of 1,775 patients who were randomized to verapamil or matching placebo in the Danish Verapamil Infarction Trial-II in the years 1985 to 1987. During 10,474 patient-years, no increased risk of cancer was observed for the verapamil-treated men or women compared with the age- and sex-matched background population.
Sajadieh
A
A
Department of Cardiovascular Medicine, H:S Bispebjerg Hospital, Copenhagen, Denmark.
Storm
H H
HH
Hansen
J F
JF
D000368:Aged; D002121:Calcium Channel Blockers / Q000009:adverse effects* / Q000627:therapeutic use; D003327:Coronary Disease / Q000188:drug therapy; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000139:chemically induced*; D016032:Randomized Controlled Trials as Topic; D012306:Risk; D014700:Verapamil / Q000009:adverse effects* / Q000627:therapeutic use
D002121:Calcium Channel Blockers; D014700:Verapamil